Transcept's Drug for Obsessive Compulsive Disorder Fails

Reuters (12/21/12) Dey, Esha
Transcept Pharmaceuticals says that its mid-stage trial of TO-2061, its experimental drug for treating obsessive compulsive disorder, did not achieve its primary objective of showing improvements in treating symptoms of the condition better than a placebo. Further analyses of the of the drug will be performed early next year. Transcept Pharmaceuticals says that the additional reviews of data from the analyses will help it decide whether to continue with its efforts to develop TO-2061.

Read the complete article

Share |

Sponsor Highlights